In this study, we examined changes in the plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tissue-type plasminogen activator (tPA)/PAI-I complex in patients with disseminated intravascular coagulation (DIC) and in those with thrombotic thrombocytopenic purpura (TTP) to investigate the fibrinolytic function and its relation to organ failure, The plasma levels of total PAI-I and tPA/PAI-I complex were significantly higher in patients with DIC, pre-DIC, and TTP than in those with non-DIC. The plasma levels of thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), D-dimer, thrombomodulin (TM), total PAI-I, and tPA/PAI-I complex were significantly higher in patients with organ failure than in those without organ failure. The plasma levels of total PAI-I and tPA/PAI-I complex were markedly increased in patients with acute leukemia. The
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' ~ ~'). inhibits both tissue-type plasminogen activator and urokinase-type plasminogen activator (uPA) (2) (3) (4) . activator inhibitor-1 is therefore añ important regulator of extracellular proteolysis and fibrinnolysis that plays important role in turnover of the extracellular matrix. P.a~~-I is a relatively unstable molecule that is rapidly converted ~c~ ~. latent ~'~rm~ it can be also converted its active form after treatment with denaturants (5) . plasma, PAI-1 forms stable stoichiometric complexes with tPA (6) . As PAI-I levels rise in plasma, jthe fraction of tPA in the active form falls while the 'issue-type activator/plasminogen activator inhibitor-I (tPA/PAI-1) complex levels rise (7, 8) . The increase in tPA/PAI-I complex levels correlates with the increase in the levels of PAI-I.
Disseminated intravascular coagulation (DIC) is characterized by generation and deposition of fibrin in the microvasculature of various organs, which is believed to be an important contributing factor for the development of multiple organ failure (MOF) (9) . Progressive inhibition of the fibrivcalytic during DIC may ultimately result in impaired fibrin dissolution, with subsequent increased formation of microthrombi causing MOF. Thrombotic thrombocytopenic purpura (TTP) is a syndrome characterized by microangiopathic hemolytic anemia, thrc~mbo~ytc~p~nia~ fever, neurologic symptoms, and renal dysfunction (10, 11) . Thrombotic complications in this disorder are caused by the occlusion of small arteries by platelet thromboembolic. There is also evidence that von Willebrand factor (vWF) released from endothelial cells is involved in the pathophysiology of TTP (12, 13) . ' The degree of vascular endothelial cell damage may be good indicators of prognosis and pathologic changes in patients with TTP ( l ~.}.
In recent years, much attention has been paid to the role of PAI-I in DIC or sepsis, because DIC enhances the fibrinolytic state (15, 16) . Although DIC is initiated by the activation of the cc~n~ulative pathway and platelets, the development of ir~tr~v~s~c~lnr thrombosis involves the activation of the fibrinolytic system. Bleeding tendency may be caused by overactivation of the fibrinolytic system, whereas organ failure may result from inhibition of the fibrinolytic system.
In this study, we examined changes in the plasma levels of tPA/PAI-I complex and total PAI-I in patients with DIC and TTP to investigate the fibrinolytic function and its relation to organ failure.~A
'TI~R~~1LS AND METHODS
This study comprised 39 patients with DIC, ?3 with pre-DIC, 1 8 with non-DIC, and 29 with TTP. The diagnosis of DIC was based on a modified version of the ' criteria established by the Japanese Ministry of Health and Welfare (17, 18) . Pre-DIC was defined as the condition at least 1' we~k before the onset of DIC (19) . Organ failure was considered to be present for the lung when the Pea02 was 50 mmHg or less, and for the kidney when the creatinine was 3 m~IdL c~~'le~~;~ when symptoms of shock for heart failure were present, and when the patient was in a coma or responded only to pain. The underlying disease of patients with DIC, pre-DIC, or DIC included acute leukemia (22 patients), chronic leukemia (8 patients), malignant lymphoma (70 patients), other hematologic disorders (15 patients), solid cancer (44 patients), sepsis (7 patients), and other diseases (77 patients) (Table I ) .
Plasma samples in patients with DIC and TTP were collected before the treatment and stored at -80°C until use. Plasma levels of thrombin-antithrombin complex DIC, disseminated intrava~,cular coagulation,; TTP, thrombotic thrombocytopenic purpura.: TAT, thrombin-antithrombtn complex: PPIC, plasmin-plasmin inhibitor complex,: TM, thrombomodulin; PAIl, pl~stninc~~~n activator inhibitor-1: tPA, tissue ptasminogen activator.
(TAT), plasmin-pla;min inhibitor complex (PPIC), Ddimer, and thrombomodulin (TM) were measured by enzyme-linked immunosorbent. assay (ELISA) using the following kits: TAT test (Kc~ku~a~-Shi~~k~; ~~t~~, Japan), PIC test (Kokusai-Shiyaku), D-dimer test (Kokusai-Shiyaku), and TM test '(I~c~ku~~i-Shiyaku).
The plasma levels of tPA/PAI-I complex were measured by a two-step sandwich ELISA (Kokusai-Shiyaku) using a pc~lye Icanal antibody against human PAI-I and polyclonal anti-tPA antibody (20) . The levels of total PAI-I were measured using an ELISA kit ~LI~IA tPAl test, Dia-Iatron, Tokyo, Japan) by the latex agglutination immunoassay.
Data are as the means ±' standard deviation.
Statistical difference between two groups was assessed by the Wilcoxon test, and among three groups by analysis of variance (AINtJt~~~.
RESULTS
The plasma levels of TAT, PPIC, D-dimer and TM were significantly higher ~ ~ 0,0 1 ) in patients with DIC, pre-DIC, and TTP than in those with non-DIC. The plasma levels of fibrinogen were significantly lower ~ < 0.01) in patients with DIC than in non-DIC, pre-DIC, or TTP patients ( Table 2 ). The plasma levels of tPA/PAI-I complex and total PAI-1 in healthy subjects were 6.5 ± 2.8 ng/mL and 12.5 ± 2.0 ng/mL, respectively. The plasma levels of total PAI-I were significantly higher (;~ < 0.01) in patients with DIC, pre-DIC, and TTP than in those with non-DIC and in healthy volunteers (Fig. 1) ; the plasma levels of tPA/PAI-I complex were significantly higher (p' < 0.05) in patients with DIC, pre-DIC, and TTP than in those with non-DIC (Fig. 2 ). In Values are expressed as mean ± standard deviation. ' p .~ ~.0 ~ , TAT, thrombin-antithrombin complex; PPIC, plasmin-plasmin inhibitor complex; TM, thrombomodulin; PAI-1, plasminogen activator inhibitor-1; tPA, tissue pla~ntino~un activator, most cases, the plasma levels of tPA/PAI-I complex and total PAI-I decreased during the clinical course of DIC after the treatment. The plasma levels of total PAI-I were significantly hi~h~r ~ ~ 0.01) in patients with organ failure (203.4 ± 37.1 ng/mL) than in those without organ failnre (37.3 ± 3.2 ng/mL) (Fig. 3 ). The plasma levels of tPA/PAI-I complex were significantly higher~~ ~ 0.05) in patients with organ failure (56.7 ± !9.5 ng/mL) than in those without organ failure (14.3 ± 0.8 ng/mL) (Fig. 4 ). No significant difference was observed in the levels of fibrinogen between patients with and without organ failure. The plasma levels of TAT, PPIC, D-dimer, and TM were also significantly higher in patients with organ failure than in those without organ f~ziltare (Table 3) . Table 4 describes hemostatic molecular markers and underlying,-diseases of patients with DIC. Both total PAI-I and TPAIPAI-I complex were markedly increased in patients with acute leukemia. The plasma levels of total PAI-I were markedly increased in patients with sepsis and solid cancer. The 'pla~m~ levels of tPA/PAI-I complex did not change significantly. In all cases, the plasma levels of total PAI-I or tPA/PAl-l complex were not significantly correlated with other hemostatic markers (Table 5 ). There was a significant correlation between total PAI-I and TM in patients with non-DIC, and between tPA/PAI-I complex and total PAI-I or TAT in patients with pre-DIC. No significant correction was found between total PAI-I and tPA/PAI-I complex in patients with DIC. A significant correlation was found between total PAI-I and PPIC in patients with TTP.
DISCUSSION
The plasma levels of total PAI-1 or tPA/PAI-I complex were markedly higher in patients with DIC, pre-DIC, and TTP, suggesting that both tPA and PAI-1 levels increased in these conditions. These findings suggest that the plasma levels of total PAI-I and tPA/PAI-I complex may be useful markers for the diagnosis of DIC, as are TAT, PPIC, D-dimer, and TM. Increased levels of plasma ' PAI-I were reported in patients with DIC ( I7,~ 1 ): tPA and PAI-I are probably released from vascular endothelial cells after stimulation by mediators (22) . The plasma levels of total PAI-1, tPA/PAI-I complex, TAT, PPIC, D-dimer, and TM were significantly increased in patients with organ failure. These data suggest that the increase of total PAI-I and tPA/PAI-I complex is due to organ failure caused by microthrombus formation. Multiple organ failure is a serious clinical condition associated commonly with DIC (23, 24) . Recent studies have suggested the relationship between increased levels of PAI-I and the development of MOF in patients with DIC (25, 26) . In this study, moderate or marked elevation in the plasma levels of total PAI-I and tPA/PAI-I complex was observed in most cases with DIC or TTP, particularly in patients with acute leukemia and sepsis. Both total PAI-I I and tPAI~'AI-I complex were markedly increased in patients with'ac;ute leukemia. The levels of total PAI-1, but not those of the tPA/PAI-I complex, were significantly increased in patients with sepsis and solid cancer. Therefore, the tPA/PAI-I complex/total PAI-I ratio is high in acute leukemia, suggesting that this disease is associated with hyperfibrinolysis. Conversely, the tPA/PAI-I complex/total PAI-1 ratio is low in sepsis, suggesting that patients with sepsis are in a state of hypofibrinolysis. These findings suggest that patients with leukemia may. have a bleeding tendency and that patients with sepsis tend to have MOF. The of total PAI-I in TTP 5. ~',~l~tir~taslu~~~ f~~oM~ P<4/-/ and tPAIPAI-l c~c~~~te.x with other he~ic~st~cti~° rr~urke~-* p < 0.05. PAI-1, activator inhibitor-1, tPA. tissue plasminogen activator; TAT, thrombin-antithrombin complex, PPIC, plasmin-plasmin inhibitor complex; TM, thrombomodulin; DIC, disseminated intravascular coagu)ation: TTP. thrombotic thrombocytopenic purpura. may be due to vascular endothelial cell injury because the ratio is low. In all cases, total PAI-I or tPAlPAI-1 complex was not significantly correlated with other hemostatic markers. These data suggest that ~IC reflects different pathologic conditions; the plasma PAI-I levels may reflect not only DIC but also organ failure.
In brief, this study showed that the plasma levels of total PAI-I and tPA/PAI-I complex are increased in most cases of DIC and TTP, particularly in those with acute leukemia and sepsis; these abnormalities of the fibrinolysis system were more evident in DIC with organ failure. !
